eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
3/2021
vol. 72
 
Share:
Send email
Share:
abstract:
Original paper

The relationship between PD-L1 expression and tumor driver gene mutations and survival in non small cell lung carcinoma

Kin Iong Chan
1
,
Hong Ting Vong
1
,
Wai Kuou Chu
2
,
Kun Cheng
3
,
Xue Yun Zhong
4
,
Jian Ming Wen
1

  1. Department of Pathology, Kiang Wu Hospital, Macao Special Administrative Region, China
  2. Department of Surgery, Kiang Wu Hospital, Macao Special Administrative Region, China
  3. Department of Internal Medicine, Kiang Wu Hospital, Macao Special Administrative Region, China
  4. Department of Pathology, Medical School of Jinan University, Guangzhou 510632, China
Pol J Pathol 2021; 72 (3): 222-228
DOI: https://doi.org/10.5114/pjp.2021.111772
Online publish date: 2022/01/19
View full text Get citation
 
PlumX metrics:
To explore the relationship between PD-L1 expression and gene mutations and survival. PD L1, ALK and MET protein expression were detected by immunohistochemistry, and EGFR gene mutation by RT-PCR in 209 cases of NSCLC. The correlations between PD-L1 expression and gene mutations, clinicopathological features and survival was analyzed. PD-L1 was expressed in 99/209 cases (47.4%) of NSCLC, including score 1 (≥ 1% to < 5%) 23 cases (11%), score 2 (≥ 5% to < 50%) 36 cases (17.2%), and score 3 (> 50%) 40 cases (19.1%). There were 89 cases (42.6%) of EGFR mutation, 12 (5.7%) of ALK and 90 (43.1%) of MET protein positive. PD-L1 positive expression occurred more frequently in men and non-adenocarcinoma, and was negatively correlated with EGFR mutation and histological differentiation of NSCLC. PD-L1 expression was concordant in primary and metastatic cancers. There was no any effect of PD-L1 expression on overall survival of patients with NSCLC. These results suggested that PD-L1 expression is not an independent risk factor for survival of patients with NSCLC. Because of mutual complementarities of PD-L1 expression and EGFR mutation in NSCLC, both should be simultaneously detected for the patients to achieve eligible treatments.
keywords:

NSCLC, PD-L1, EGFR; survival
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.